| Sign In to gain access to subscriptions and/or personal tools. |
An Update on Monoclonal Antibody Therapies in Multiple SclerosisUniversity of Kentucky College of Medicine, Lexington
University of Kentucky College of Medicine, Lexington, worjun{at}aol.com
Multiple sclerosis (MS) is a complex disease that causes a great deal of disability, especially in the young adult population. There have been several immunomodulatory agents that have been approved by the Food and Drug Administration for MS, including glatiramer acetate, interferon-ß1a and -ß1b, mitoxantrone, and corticosteroids. The effectiveness of these therapies has not been optimal, and drugs, such as monoclonal antibodies, that more selectively target the pathogenetic process of MS have been sought. These agents have their own intrinsic limitations such as systemic inflammatory reactions, induction of neutralizing antiantibodies, and even life-threatening infectious processes. The agent that has been in the forefront of the discussion is natalizumab, a monoclonal antibody (mAb) against
Key Words: Monoclonal antibody • therapy • multiple sclerosis.
Journal of Pharmacy Practice, Vol. 20, No. 2,
167-180 (2007) |
|||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
4 integrin, which shows much promise in suppressing MS activity. However, 3 individuals treated with natalizumab developed a life-threatening infection, progressive multifocal leukoencephalopathy. This article reviews the role of mAbs in the treatment of MS, particularly their advantages over other drugs and their limitations, which have to be overcome for these agents to be at the forefront in the treatment of MS.